Business Wire

WisdomTree Announces Private Offering of $130.0 Million of Convertible Senior Notes


WisdomTree, Inc. (NYSE: WT) (“WisdomTree”), a global financial innovator, today announced its intention to offer, subject to market conditions and other factors, $130.0 million aggregate principal amount of its convertible senior notes due 2028 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). WisdomTree also expects to grant the initial purchaser of the notes an option to purchase, for settlement during a period of 13 days from, and including, the date the notes are first issued, up to an additional $20.0 million aggregate principal amount of the notes.

WisdomTree intends to use a portion of the net proceeds from the offering to finance the concurrent repurchase of up to approximately $115.0 million in aggregate principal amount of its 4.25% convertible senior notes due 2023 (the “2023 notes”) as described below, with the remainder to be used for working capital and other general corporate purposes. Any remaining 2023 notes outstanding will be settled no later than maturity.

Prior to May 15, 2028, the notes will be convertible at the option of the holders of the notes only upon the satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, WisdomTree will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at WisdomTree’s election, in respect of the remainder, if any, of WisdomTree’s conversion obligation in excess of the aggregate principal amount of the notes being converted. The notes will also be redeemable, in whole or in part, for cash at WisdomTree’s option at any time, and from time to time, on or after August 20, 2025 in certain circumstances. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. The interest rate, conversion rate and other terms of the notes are to be determined upon pricing of the offering.

Contemporaneously with the pricing of the notes in the offering, WisdomTree intends to enter into separate privately negotiated transactions with certain holders of the 2023 notes to repurchase up to approximately $115.0 million in aggregate principal amount of the 2023 notes on terms to be negotiated with such holders (each a “note repurchase” and collectively the “2023 notes repurchases”). The terms of each note repurchase are anticipated to be negotiated with certain holders of 2023 notes on an individual basis and will depend on several factors, including the market price of WisdomTree’s common stock and the trading price of the 2023 notes at the time of each such note repurchase. No assurance can be given as to how much, if any, of the 2023 notes will be repurchased or the terms on which they will be repurchased. The consideration for any such note repurchases will be cash financed with a portion of the net proceeds from the offering. Any remaining 2023 notes outstanding will be settled no later than maturity.

WisdomTree expects that certain holders of 2023 notes that sell their 2023 notes in negotiated transactions with WisdomTree may enter into or unwind various derivatives with respect to WisdomTree’s common stock and/or purchase shares of its common stock in the market. The amount of WisdomTree’s common stock that such holders purchase may be substantial in relation to the historic average daily trading volume of the common stock. In addition, WisdomTree expects that certain purchasers of the notes offered in the offering may establish a short position with respect to its common stock by short selling the common stock or by entering into short derivative positions with respect to the common stock, in each case, in connection with the offering. The net effect of the above market activities by holders of 2023 notes and purchasers of the notes offered in the offering could increase (or reduce the size of any decrease in) or decrease (or reduce the size of any increase in) the market price of WisdomTree’s common stock and/or the market price of the notes offered in the offering, and WisdomTree cannot predict the magnitude of such market activities or the overall effect they will have on the market price of the notes and/or the market price of its common stock.

The notes will only be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes and the common stock issuable upon conversion of the notes, if any, have not been and will not be registered under the Securities Act, or any state securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About WisdomTree

WisdomTree is a global financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. We empower investors to shape their future and support financial professionals to better serve their clients and grow their businesses. WisdomTree is leveraging the latest financial infrastructure to create products that provide access, transparency and an enhanced user experience. Building on our heritage of innovation, we are also developing next-generation digital products and structures, including digital funds and tokenized assets, as well as our blockchain-native digital wallet, WisdomTree Prime™.

WisdomTree currently has approximately $88.1 billion in assets under management globally.

WisdomTree® is the marketing name for WisdomTree, Inc. and its subsidiaries worldwide.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that are based on WisdomTree’s management’s beliefs and assumptions and on information currently available to management. Although WisdomTree believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or WisdomTree’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond WisdomTree’s control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, the risks described below. If one or more of these or other risks or uncertainties occur, or if WisdomTree’s underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this press release completely and with the understanding that WisdomTree’s actual future results may be materially different from any future results expressed or implied by these forward-looking statements.

In particular, forward-looking statements in this press release may include statements about the proposed terms of the notes, the size of the notes offering, including the option to purchase additional notes to be granted to the initial purchaser, the expected use of the proceeds from the sale of the notes and the potential effects of the 2023 notes repurchases on WisdomTree’s common stock and the market price of the notes, and other statements contained in this press release that are not historical facts. Forward-looking statements are subject to many risks and uncertainties, including without limitation, risks related to or associated with whether WisdomTree will consummate the offering of the notes on the expected terms, or at all, which could differ or change based upon market conditions or other reasons, and the other risks set forth under the caption “Risk Factors” in WisdomTree’s Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

Category: Business Update

To view this piece of content from, please give your consent at the top of this page.

Contact information

Media Relations
WisdomTree, Inc.
Jessica Zaloom
+1.917.267.3735 /

Investor Relations
WisdomTree, Inc.
Jeremy Campbell

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Announces First-Quarter 2023 Results Conference Call20.3.2023 20:00:00 EET | Press release

SLB (NYSE: SLB) will hold a conference call on April 21, 2023 to discuss the results for the first quarter ending March 31, 2023. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at until May 21, 2023, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402) 970-0847 outside of North

Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS® ▼in the European Economic Area, the United Kingdom, Australia and Brazil20.3.2023 19:28:00 EET | Press release

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. Theramex will commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil. “Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. We are delighted to be entering into this partnership with Radius, building on our expanding portfolio and aligning missions to reduce fracture risks for many postmenopausal women suffering from osteoporosis.” - Rob Stewart, CEO of Theramex “We are thrilled to have Theramex bring abaloparatide to postmenopausal women in Europe who coul

New Stilla Ruby Chip and naica® system 21 CFR Part 11 compliance enable full automation of digital PCR testing for clinically-oriented applications20.3.2023 18:48:00 EET | Press release

Stilla Technologies, the multiplex digital PCR company, has recently introduced the Ruby Chip, the industry’s first ‘load-and-go’ consumable for digital PCR, optimized for its naica® system. The naica® system, which now supports 21 CFR Part 11 regulatory compliance, is part of a fully-automated sample-to-results workflow – the first of its kind for digital PCR. This platform serves the growing throughput and regulatory requirements of many clinically-oriented applications, such as in cell and gene therapy development and quality control or for liquid biopsy applications for the detection of circulating tumor DNA (ctDNA). With adjustable throughput of up to 96 samples processing capability in under three hours, the Ruby Chip is designed with standard SBS plate spacing compatible with multichannel pipettes for manual loading and can be easily integrated with common liquid handling robots. A key feature of the Ruby Chip is that it comes ready-to-use and preloaded with sealed chambers, ena

FlexTrade Hires Senior Sell-Side OMS Specialist to Drive Growth in EMEA Region20.3.2023 17:30:00 EET | Press release

FlexTrade Systems (@FlexTrade), a global leader in multi-asset order and execution management systems, announces the appointment of Rajiv Shah as Head of Sales in EMEA for its sell-side OEMS, FlexOMS. FlexOMS, the flagship OMS platform within FlexTrade's suite of sell-side solutions, is designed to boost trading efficiency by simplifying the complexities of today's trading workflows. The open-architecture trading solution supports high-touch and low-touch businesses by providing a unified multi-asset platform across cash, program trading, futures & options, ETF, swaps, fixed income, and foreign exchange workflows. In this newly created role, Rajiv will drive FlexTrade's business strategy and growth of the solutions to trading desks within EMEA. Rajiv brings over 30 years of experience in financial technology with a proven track record in designing and executing sales and business growth strategies across the front and middle-office trading space within enterprise-grade software firms.

LambdaTest improves its Selenium automation testing experience with the addition of its AI-powered integrated test intelligence20.3.2023 17:30:00 EET | Press release

LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the addition of advanced AI-powered test intelligence features to its Selenium testing cloud offering. With this latest development, LambdaTest will now enable enterprises with deeper insights into their test execution process and help them better streamline their quality assurance process. LambdaTest has been constantly working on enhancing its Selenium automation testing cloud and the test intelligence feature is the latest addition to the list. Over the last quarter, LambdaTest has added features like support for all Selenium 4 versions, including support for BiDi protocol, enhanced low-latency live streaming of test execution for faster test feedback, and the ability to group tests by tags for better manageability. Just last month, LambdaTest added Selenium tracing that allows users to visualize each command flow and each test error along with its telemetry data. All these features combi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom